BridGene Biosciences
Sunnyvale
About BridGene Biosciences
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $78.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: bridgenebio.com
- Phone: .(408) 498-8127
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bridgene-biosciences-119019 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.